HUTCHMED's oncology segment is dedicated to the discovery, development, and commercialization of targeted therapies and immunotherapies for various cancer types. This segment focuses on addressing unmet medical needs in solid tumors and hematological malignancies. Key research and development activities include preclinical studies, clinical trials (Phase I, II, and III), and biomarker identification to personalize treatment approaches. The company utilizes advanced technologies such as small molecule inhibitors and monoclonal antibodies to target specific cancer pathways. Fruquintinib, Savolitinib, and Surufatinib are examples of key assets in this segment, targeting colorectal cancer, non-small cell lung cancer, and neuroendocrine tumors, respectively. The ultimate goal is to improve patient outcomes and quality of life through innovative cancer treatments. Regulatory approvals and strategic partnerships are crucial for market access and commercial success.

The immunology segment at HUTCHMED focuses on developing novel therapies for immunological diseases and related conditions. This involves research into the underlying mechanisms of immune dysfunction and the identification of potential therapeutic targets. The company employs a range of technologies, including small molecule inhibitors and biologics, to modulate the immune system and restore balance. HMPL-523, a spleen tyrosine kinase inhibitor, is a key asset in this segment, targeting hematological cancers and chronic immune diseases. Clinical trials are conducted to evaluate the safety and efficacy of these therapies in various patient populations. The goal is to provide effective treatments for patients with autoimmune disorders, inflammatory diseases, and other immune-related conditions, improving their overall health and well-being. Strategic collaborations and partnerships are essential for expanding the reach and impact of HUTCHMED's immunology portfolio.